{
    "nct_id": "NCT05483023",
    "official_title": "18-fluorofuranylnorprogesterone (FFNP) Positron Emission Tomography-Magnetic Resonance Imaging (PET/MRI) as a Potential Biomarker of Response to Progesterone Therapy in Complex Atypical Hyperplasia (CAH) and Grade 1 Endometrial Cancer (EC)",
    "inclusion_criteria": "* Female age 18 or older\n* Histologically confirmed CAH or Grade 1 EC\n* No prior surgical or hormonal treatment for CAH or Grade 1 EC\n* Planned treatment with levonorgestrel-releasing intrauterine device (LR-IUD) for CAH or grade 1 EC\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Inability to complete PET/MR scans due to severe claustrophobia\n* Institutionalized subject (prisoner or nursing home subject)\n* Implanted metallic devices, parts, vascular clips, or other foreign bodies.\n* Known hypersensitivity to gadolinium or FFNP or to any component of gadolinium or FFNP refractory to standard medications (antihistamines, steroids)\n* Impaired kidney function (serum creatinine level > 1.8 mg/dl or a glomerular filtration rate < 60 as approximated using serum creatinine levels) unless anuric and on dialysis.\n* Any woman who is pregnant or has reason to believe she is pregnant (the possibility of pregnancy has to be excluded by negative urine (Î²-HCG) results, obtained within 24 hours before FFNP administration, or on the basis of patient history)\n* Prior hormone treatment for breast cancer",
    "miscellaneous_criteria": ""
}